



# Global Pharmaceutical company

Managing end-to-end data integration activities



## Client challenge

Our client, a global pharmaceutical organisation, acquired two late-stage biotechnology companies. KPMG was brought in to manage the data surveying and allocation of treatment plans across the two integration projects. Challenges included the varying nature of unstructured data storage and differing record retention schedules, with a huge volume of clinical, patient and GxP data stored in unstructured data sources. In addition, there was a lack of established data management protocols in the target, leading to data storage across multiple platforms.

## Our approach

Our specialists carried out data discovery across all business functions. This enabled us to identify entangled, GxP (regulatory and auditable data), legal preservation hold and intellectual property data. We also identified areas of data leakage and addressed gaps via a leaver checklist and enhanced DLP monitoring.

We created data disposition teams and a hierarchy of data ownership, which enabled data owners from both entities to work together on data discovery and disposition planning. This included a GxP-compliant data transfer processes with tech, legal and risk teams.

An auditable governance structure was implemented to ensure comprehensive control of data decisions taken by the business, and we established a repeatable, iterative framework for managing the implementation of planned data migration waves/drops.

## Benefits for the client

Our client benefited through the early discovery of data hotspots and potential points of data leakage, along with proactive handling of any areas of risk.

The comprehensive data inventory we created allowed for full auditable tracking of data movement and decisions in line with GxP protocols.

Legacy data identified and deleted where no longer required, leading to significant data migration and storage requirements and costing.

The client was also able to leverage the bespoke framework across other areas in the organisation, leading to a reduction in the risk profile and lower costs.

The information contained herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavour to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

© 2023 KPMG LLP, a UK limited liability partnership and a member firm of the KPMG global organisation of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organisation.

CREATE | CRT151062A | September 2023